- Home
- USCB vs ANNX Comparison
USCB vs ANNX Comparison
Compare USCB & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- ANNX
- Stock Information
- Founded
- USCB 2002
- ANNX 2011
- Country
- USCB United States
- ANNX United States
- Employees
- USCB N/A
- ANNX N/A
- Industry
- USCB Major Banks
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- ANNX Health Care
- Exchange
- USCB Nasdaq
- ANNX Nasdaq
- Market Cap
- USCB 330.1M
- ANNX 334.1M
- IPO Year
- USCB 2021
- ANNX 2020
- Fundamental
- Price
- USCB $16.69
- ANNX $3.13
- Analyst Decision
- USCB Strong Buy
- ANNX Strong Buy
- Analyst Count
- USCB 3
- ANNX 4
- Target Price
- USCB $22.00
- ANNX $13.00
- AVG Volume (30 Days)
- USCB 22.1K
- ANNX 2.2M
- Earning Date
- USCB 10-23-2025
- ANNX 11-13-2025
- Dividend Yield
- USCB 2.34%
- ANNX N/A
- EPS Growth
- USCB 67.08
- ANNX N/A
- EPS
- USCB 1.47
- ANNX N/A
- Revenue
- USCB $88,094,000.00
- ANNX N/A
- Revenue This Year
- USCB $25.60
- ANNX N/A
- Revenue Next Year
- USCB $5.04
- ANNX N/A
- P/E Ratio
- USCB $11.64
- ANNX N/A
- Revenue Growth
- USCB 32.06
- ANNX N/A
- 52 Week Low
- USCB $14.50
- ANNX $1.29
- 52 Week High
- USCB $21.86
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- USCB 43.47
- ANNX 58.97
- Support Level
- USCB $16.36
- ANNX $2.87
- Resistance Level
- USCB $17.57
- ANNX $3.30
- Average True Range (ATR)
- USCB 0.47
- ANNX 0.21
- MACD
- USCB -0.04
- ANNX -0.02
- Stochastic Oscillator
- USCB 26.86
- ANNX 55.34
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.